Drugs / Budesonide/formoterol
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00633919 Comparator | Jul 2006 → Dec 2008 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent viatris.com ↗ |
| 2021-03-08 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide/formoterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633919 ↗ |
| Known as | Symbicort | “Budesonide/formoterol inhaler (80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting β2-agonist; Symbicort®).” NCT00633919 ↗ |
| Route | Inhaled | “Budesonide/formoterol inhaler (80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting β2-agonist; Symbicort®).” NCT00633919 ↗ |